WHO Classification of Tumours Editorial Board. Endocrine and neuroendocrine tumours. Lyon (France): International Agency for Research on Cancer; 2022. (WHO classification of tumours series, 5th ed.; vol. 10). Available from: https://tumourclassification.iarc.who.int/chapters/53.

Nosé V, Gill A, Teijeiro JMC, Perren A, Erickson L. Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. Endocr Pathol. 2022 Mar;33(1):197-227. https://doi.org/10.1007/s12022-022-09705-5.

Article  PubMed  Google Scholar 

Anglesio MS, Wang Y, Yang W, Senz J, Wan A, Heravi-Moussavi A, Salamanca C, Maines-Bandiera S, Huntsman DG, Morin GB. Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. J Pathol. 2013 Feb;229(3):400-9. https://doi.org/10.1002/path.4135.

Foulkes WD, Priest JR, Duchaine TF. DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer. 2014 Oct;14(10):662-72. https://doi.org/10.1038/nrc3802.

Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022 Mar;33(1):27-63. https://doi.org/10.1007/s12022-022-09707-3.

Khan NE, Bauer AJ, Schultz KAP, Doros L, Decastro RM, Ling A, Lodish MB, Harney LA, Kase RG, Carr AG, Rossi CT, Field A, Harris AK, Williams GM, Dehner LP, Messinger YH, Hill DA, Stewart DR. Quantification of Thyroid Cancer and Multinodular Goiter Risk in the DICER1 Syndrome: A Family-Based Cohort Study. J Clin Endocrinol Metab. 2017 May 1;102(5):1614-1622. https://doi.org/10.1210/jc.2016-2954.

Condello V, Poma AM, Macerola E, Vignali P, Paulsson JO, Zedenius J, Basolo F, Juhlin CC. Prevalence, Molecular Landscape, and Clinical Impact of DICER1 and DGCR8 Mutated Follicular-Patterned Thyroid Nodules. J Clin Endocrinol Metab. 2024 Jun 17;109(7):1733-1744. https://doi.org/10.1210/clinem/dgae034.

Onder S, Mete O, Yilmaz I, Bayram A, Bagbudar S, Altay AY, Issin G, Terzi NK, Iscan Y, Sormaz IC, Tunca F, Senyurek YG, Yegen G. DICER1 Mutations Occur in More Than One-Third of Follicular-Patterned Pediatric Papillary Thyroid Carcinomas and Correlate with a Low-Risk Disease and Female Gender Predilection. Endocr Pathol. 2022 Dec;33(4):437-445. https://doi.org/10.1007/s12022-022-09736-y.

Yegen G, Altay AY, Yılmaz İ, İşcan Y, Sormaz İC, Aksakal N, Önder S, Mete Ö. DICER1 Mutations Do Not Always Indicate Dismal Prognosis in Pediatric Poorly Differentiated Thyroid Carcinomas. Endocr Pathol. 2023 Sep;34(3):279-286. https://doi.org/10.1007/s12022-023-09780-2.

Rio Frio T, Bahubeshi A, Kanellopoulou C, Hamel N, Niedziela M, Sabbaghian N, Pouchet C, Gilbert L, O’Brien PK, Serfas K, Broderick P, Houlston RS, Lesueur F, Bonora E, Muljo S, Schimke RN, Bouron-Dal Soglio D, Arseneau J, Schultz KA, Priest JR, Nguyen VH, Harach HR, Livingston DM, Foulkes WD, Tischkowitz M. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA. 2011 Jan 5;305(1):68-77. https://doi.org/10.1001/jama.2010.1910.

Jensen RD, Norris HJ, Fraumeni JF Jr. Familial arrhenoblastoma and thyroid adenoma. Cancer. 1974 Jan;33(1):218-23. https://doi.org/10.1002/1097-0142(197401)33:1<218::aid-cncr2820330132>3.0.co;2-z.

Javert CT, Finn WF. Arrhenoblastoma; the incidence of malignancy and the relationship to pregnancy, to sterility, and to treatment. Cancer. 1951 Jan;4(1):60-77. https://doi.org/10.1002/1097-0142(195101)4:1<60::aid-cncr2820040106>3.0.co;2-0.

Chernock RD, Rivera B, Borrelli N, Hill DA, Fahiminiya S, Shah T, Chong AS, Aqil B, Mehrad M, Giordano TJ, Sheridan R, Rutter MM, Dehner LP, Foulkes WD, Nikiforov YE. Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations. Mod Pathol. 2020 Jul;33(7):1264-1274. https://doi.org/10.1038/s41379-020-0458-7.

Whaley RD, Gupta S, Manninen MC, O'Brien DR, Erickson LA. Clinicopathologic and Molecular Analysis of 15 Pediatric and Young Adult Patients with High-Grade Non-anaplastic Thyroid Carcinoma. Endocr Pathol. 2024 Dec;35(4):397-410. https://doi.org/10.1007/s12022-024-09842-z.

Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G, Rosai J. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007 Aug;31(8):1256-64. https://doi.org/10.1097/PAS.0b013e3180309e6a.

Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, Shah JP, Singh B, Ghossein RA. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer. 2006 Mar 15;106(6):1286-95. https://doi.org/10.1002/cncr.21739.

Juhlin CC, Stenman A, Zedenius J. Macrofollicular variant follicular thyroid tumors are DICER1 mutated and exhibit distinct histological features. Histopathology. 2021 Oct;79(4):661-666. https://doi.org/10.1111/his.14416.

Condello V, Roberts JW, Stenman A, Larsson C, Viswanathan K, Juhlin CC. Atrophic changes in thyroid tumors are strong indicators of underlying DICER1 mutations: a bi-institutional genotype-phenotype correlation study. Virchows Arch. 2024 Jul;485(1):105-114. https://doi.org/10.1007/s00428-024-03802-y.

Wasserman JD, Sabbaghian N, Fahiminiya S, Chami R, Mete O, Acker M, Wu MK, Shlien A, de Kock L, Foulkes WD. DICER1 Mutations Are Frequent in Adolescent-Onset Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2018 May 1;103(5):2009–2015. https://doi.org/10.1210/jc.2017-02698. Erratum in: J Clin Endocrinol Metab. 2018 Aug 1;103(8):3114. https://doi.org/10.1210/jc.2018-01190.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405–24. https://doi.org/10.1038/gim.2015.30.

Aliyev E, Ladra-González MJ, Sánchez-Ares M, Abdulkader-Nallib I, Piso-Neira M, Rodríguez-Carnero G, Vieiro-Balo P, Pérez-Becerra R, Gude-Sampedro F, Barreiro-Morandeira F, Alvarez CV, Cameselle-Teijeiro JM. Thyroid Papillary Microtumor: Validation of the (Updated) Porto Proposal Assessing Sex Hormone Receptor Expression and Mutational BRAF Gene Status. Am J Surg Pathol. 2020 Sep;44(9):1161-1172. https://doi.org/10.1097/PAS.0000000000001522.

de Kock L, Terzic T, McCluggage WG, Stewart CJR, Shaw P, Foulkes WD, Clarke BA. DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. Am J Surg Pathol. 2017 Sep;41(9):1178-1187. https://doi.org/10.1097/PAS.0000000000000895.

Hill DA, Ivanovich J, Priest JR, Gurnett CA, Dehner LP, Desruisseau D, Jarzembowski JA, Wikenheiser-Brokamp KA, Suarez BK, Whelan AJ, Williams G, Bracamontes D, Messinger Y, Goodfellow PJ. DICER1 mutations in familial pleuropulmonary blastoma. Science. 2009 Aug 21 325(5943):965. https://doi.org/10.1126/science.1174334.

Bongiovanni M, Sykiotis GP, La Rosa S, Bisig B, Trimech M, Missiaglia E, Gremaud M, Salvatori Chappuis V, De Vito C, Sciarra A, Foulkes WD, Pusztaszeri M. Macrofollicular Variant of Follicular Thyroid Carcinoma: A Rare Underappreciated Pitfall in the Diagnosis of Thyroid Carcinoma. Thyroid. 2020 Jan;30(1):72-80. https://doi.org/10.1089/thy.2018.0607.

Ver Berne J, Van den Bruel A, Vermeire S, De Paepe P. DICER1 Mutations Define the Landscape of Poorly Differentiated Thyroid Carcinoma in Children and Young Adults: Case Report and Literature Review. Am J Surg Pathol. 2024 Oct 1;48(10):1277-1283. https://doi.org/10.1097/PAS.0000000000002265.

Albores-Saavedra J, Housini I, Vuitch F, Snyder WH 3rd. Macrofollicular variant of papillary thyroid carcinoma with minor insular component. Cancer. 1997 Sep 15;80(6):1110-6. https://doi.org/10.1002/(sici)1097-0142(19970915)80:6<1110::aid-cncr14>3.0.co;2-b.

Rutter MM, Jha P, Schultz KA, Sheil A, Harris AK, Bauer AJ, Field AL, Geller J, Hill DA. DICER1 Mutations and Differentiated Thyroid Carcinoma: Evidence of a Direct Association. J Clin Endocrinol Metab. 2016 Jan;101(1):1-5. https://doi.org/10.1210/jc.2015-2169.

de Kock L, Bah I, Revil T, Bérubé P, Wu MK, Sabbaghian N, Priest JR, Ragoussis J, Foulkes WD. Deep Sequencing Reveals Spatially Distributed Distinct Hot Spot Mutations in DICER1-Related Multinodular Goiter. J Clin Endocrinol Metab. 2016 Oct;101(10):3637-3645. https://doi.org/10.1210/jc.2016-1328.

Stolarova L, Kleiblova P, Janatova M, Soukupova J, Zemankova P, Macurek L, Kleibl Z. CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate. Cells. 2020 Dec 12;9(12):2675. https://doi.org/10.3390/cells9122675.

Pal M, Das D, Pandey M. Understanding genetic variations associated with familial breast cancer. World J Surg Oncol. 2024 Oct 10;22(1):271. https://doi.org/10.1186/s12957-024-03553-9.

Sánchez-Ares M, Cameselle-García S, Abdulkader-Nallib I, Rodríguez-Carnero G, Beiras-Sarasquete C, Puñal-Rodríguez JA, Cameselle-Teijeiro JM. Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys. Front Endocrinol (Lausanne). 2022 Feb 28;13:829103. https://doi.org/10.3389/fendo.2022.829103.

Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymańska A, Szymańska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubiński J. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004 Dec;75(6):1131-5. https://doi.org/10.1086/426403.

Siołek M, Cybulski C, Gąsior-Perczak D, Kowalik A, Kozak-Klonowska B, Kowalska A, Chłopek M, Kluźniak W, Wokołorczyk D, Pałyga I, Walczyk A, Lizis-Kolus K, Sun P, Lubiński J, Narod SA, Góźdż S. CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer. 2015 Aug 1;137(3):548-52. https://doi.org/10.1002/ijc.29426.

Bychkovsky BL, Agaoglu NB, Horton C, Zhou J, Yussuf A, Hemyari P, Richardson ME, Young C, LaDuca H, McGuinness DL, Scheib R, Garber JE, Rana HQ. Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2. JAMA Oncol. 2022 Nov 1;8(11):1598-1606. https://doi.org/10.1001/jamaoncol.2022.4071.

Brock P, Liynarachchi S, Nieminen TT, Chan C, Kohlmann W, Stout LA, Yao S, La Greca A, Jensen KE, Kolesar JM, Salhia B, Gulhati P, Hicks JK, Ringel MD. CHEK2 Founder Variants and Thyroid Cancer Risk. Thyroid. 2024 Apr;34(4):477-483. https://doi.org/10.1089/thy.2023.0529.

Cai Z, Chehab NH, Pavletich NP. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. Mol Cell. 2009 Sep 24;35(6):818-29. https://doi.org/10.1016/j.molcel.2009.09.007.

Wang N, Ding H, Liu C, Li X, Wei L, Yu J, Liu M, Ying M, Gao W, Jiang H, Wang Y. A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk. Oncogene. 2015 Oct 1;34(40):5198-205. https://doi.org/10.1038/onc.2014.443.

Aksoy F, Tezcan Unlu H, Cecener G, Guney Eskiler G, Egeli U, Tunca B, Efendi Erdem E, Senol K, Gokgoz MS. Identification of CHEK2 germline mutations in BRCA1/2 and PALB2 negative breast and ovarian cancer patients. Hum Hered. 2022 Jan 6. https://doi.org/10.1159/000521369.

Higashiguchi M, Nagatomo I, Kijima T, Morimura O, Miyake K, Minami T, Koyama S, Hirata H, Iwahori K, Takimoto T, Takeda Y, Kida H, Kumanogoh A. Clarifying the biological significance of the CHK2 K373E somatic mutation discovered in The Cancer Genome Atlas database. FEBS Lett. 2016 Dec;590(23):4275-4286. https://doi.org/10.1002/1873-3468.12449.

Bhele S, Mansour M, McGrath J, Oberley M, Feldman M, Karnezis A, Chernock R. Characterization of DICER1 Mutations in Clinically Aggressive Thyroid Carcinomas from a Large Database of Real-World Patient Samples. Lab Invest. 2023 Mar;103(3):S484-485.

de Kock L, Wu MK, Foulkes WD. Ten years of DICER1 mutations: Provenance, distribution, and associated phenotypes. Hum Mutat. 2019 Nov;40(11):1939-1953. https://doi.org/10.1002/humu.23877.

Poma AM, Condello V, Denaro M, Torregrossa L, Elisei R, Vitti P, Basolo F. DICER1 somatic mutations strongly impair miRNA processing even in benign thyroid lesions. Oncotarget. 2019 Mar 5;10(19):1785–1797. https://doi.org/10.18632/oncotarget.26639.

Ricarte-Filho JC, Casado-Medrano V, Reichenberger E, Spangler Z, Scheerer M, Isaza A, Baran J, Patel T, MacFarland SP, Brodeur GM, Stewart DR, Baloch Z, Bauer AJ, Wasserman JD, Franco AT. DICER1 RNase IIIb domain mutations trigger widespread miRNA dysregulation and MAPK activation in pediatric thyroid cancer. Front Endocrinol (Lausanne). 2023 Feb 21;14:1083382. https://doi.org/10.3389/fendo.2023.1083382.

Gullo I, Batista R, Rodrigues-Pereira P, Soares P, Barroca H, do Bom-Sucesso M, Sobrinho-Simões M. Multinodular Goiter Progression Toward Malignancy in a Case of DICER1 Syndrome: Histologic and Molecular Alterations. Am J Clin Pathol. 2018 Mar 29;149(5):379–386. https://doi.org/10.1093/ajcp/aqy004.

Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014 Oct 23;159(3):676-90. https://doi.org/10.1016/j.cell.2014.09.050.

Shin SH, Yoon JH, Son MH, Kim SJ, Park SY, Kim HY, Lee HS, Park HJ, Park BK. Follicular thyroid carcinoma arising after hematopoietic stem cell transplantation in a child with pleuropulmonary blastoma. Thyroid. 2012 May;22(5):547-51. https://doi.org/10.1089/thy.2011.0161.

Lengyel K, Lubin DJ, Hsiao WY, Sirotnikov S, Luo G, Roberts JW, Shi Q, Magliocca K, Lewis MM, Sears DL, Ilyas G, Rogers BB, Viswanathan K. Comprehensive evaluation of cytomorphologic, histologic, and molecular features of DICER1-altered thyroid lesions on FNA: A multipractice experience. Cancer Cytopathol. 2024 Jun;132(6):359-369. https://doi.org/10.1002/cncy.22805.

Juhlin CC, Mete O. Letter to the Editor: Morphological Indicators of DICER1 Mutations May Guide Somatic and Germline Testing. Thyroid. 2025 Jan;35(1):120-121. https://doi.org/10.1089/thy.2024.0556.

Jung CK, Liu Z, Hirokawa M, Bychkov A. Histological clues of DICER1 mutations in thyroid nodules. Virchows Arch. 2024 Oct;485(4):755-757. https://doi.org/10.1007/s00428-024-03915-4.

Mete O, Boucher A, Schrader KA, Abdel-Rahman O, Bahig H, Ho C, Hasan OK, Lemieux B, Winquist E, Wong R, Wu J, Chau N, Ezzat S. Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management. Endocr Pathol. 2024 Dec;35(4):293–308. https://doi.org/10.1007/s12022-024-09836-x. Epub 2024 Nov 23. Erratum in: Endocr Pathol. 2024 Dec;35(4):309–310. https://doi.org/10.1007/s12022-024-09843-y.

Cameselle-Teijeiro JM, Mete O, Asa SL, LiVolsi V. Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates. Endocr Pathol. 2021 Mar;32(1):77-101. https://doi.org/10.1007/s12022-020-09661-y.

Paulsson JO, Wang N, Gao J, Stenman A, Zedenius J, Mu N, Lui WO, Larsson C, Juhlin CC. GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours. Endocr Relat Cancer. 2020 May;27(5):295-308. https://doi.org/10.1530/ERC-19-0446.

Erler P, Keutgen XM, Crowley MJ, Zetoune T, Kundel A, Kleiman D, Beninato T, Scognamiglio T, Elemento O, Zarnegar R, Fahey TJ 3rd. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer. Surgery. 2014 Dec;156(6):1342-50. https://doi.org/10.1016/j.surg.2014.08.007.

Nadaf J, de Kock L, Chong AS, Korbonits M, Thorner P, Benlimame N, Fu L, Peet A, Warner J, Ploner O, Shuangshoti S, Albrecht S, Hamel N, Priest JR, Rivera B, Ragoussis J, Foulkes WD. Molecular characterization of DICER1-mutated pituitary blastoma. Acta Neuropathol. 2021 Jun;141(6):929-944. https://doi.org/10.1007/s00401-021-02283-6.

Thorner PS, Chong AS, Nadaf J, Benlimame N, Marrano P, Chami R, Fu L, Foulkes WD. PRAME protein expression in DICER1-related tumours. J Pathol Clin Res. 2022 May8(3):294–304. https://doi.org/10.1002/cjp2.264. https://doi.org/10.1002/cjp2.293 Erratum in: J Pathol Clin Res. 2022 Nov;8(6):579–581. https://doi.org/10.1002/cjp2.293.

Saliba M, Alzumaili BA, Katabi N, Dogan S, Tuttle RM, Zoltan A, Pandit-Taskar N, Xu B, Ghossein RA. Clinicopathologic and Prognostic Features of Pediatric Follicular Cell-derived Thyroid Carcinomas: A Retrospective Study of 222 Patients. Am J Surg Pathol. 2022 Dec 1;46(12):1659-1669. https://doi.org/10.1097/PAS.0000000000001958.

Clausen B, Wakefield C, Wu S, Slack J, Wassner A, Hollowell M, Barletta J. Non-Invasive Follicular Cell-Derived Neoplasms with High-Grade Features: A Clinicopathologic and Molecular Study. Lab Invest. 2024 Mar; 104(3): S591.

Scholfield DW, Xu B, Levyn H, Eagan A, Shaha AR, Shah JP, Tuttle RM, Fagin JA, Wong RJ, Patel SG, Ghossein R, Ganly I. High-Grade Follicular Cell-Derived Non-Anaplastic Thyroid Carcinoma: Correlating Extent of Invasion and Mutation Profile with Oncologic Outcome. Thyroid. 2025 Feb;35(2):153-165. https://doi.org/10.1089/thy.2024.0499.

Mastnikova K, Bulanova Pekova B, Kuklikova V, Vaclavikova E, Carkova J, Katra R, Fialova L, Vlcek P, Kodetova D, Chovanec M, Drozenova J, Matej R, Pacesova P, Novak Z, Procykova K, Vcelak J, Bendlova B. DICER1 Variants in Pediatric and Young Adult Thyroid Nodules. Thyroid. 2024 Oct;34(10):1225-1233. https://doi.org/10.1089/thy.2024.0188.

Meng L, Li H, Fu Y, Yu D, Tang J, Hu Y, Fei X, Yang K, Liu Z, Peng R, Zhou Y, Wang S, Yan J, Shen L, Han R, Ye L. Somatic DICER1-Mutant Benign Thyroid Nodules in Adults: A Group of Follicular Nodular Disease With Continuous Growth. J Clin Endocrinol Metab. 2024 Oct 28:dgae750. https://doi.org/10.1210/clinem/dgae750.